Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2585)	9/15/2009 4:43:38 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

BCRX was up 15.56% at its intraday H and is closing up 8.76% on volume of > 10,100,000 about 4.7x its ADV. The stock has not closed its Jul 17 UG and opened with another smaller UG today. It still has ressitance from its Sep 1 H at $13.47 besides its intaday H today at $12.40 <g> bigcharts.marketwatch.com BCRX has been able to trim its loss in the last 2Qs, in spite of the much lower revenues on the 1stQ, and since the expected earnings for the current Yr.are on the black column, the results for the pending 2 Qs should also look good by comparison to 2008 It announced today that it has signed binding letters of intent with 3 partners for distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S. Each partner will immediately begin meeting with key government officials in their respective territories to discuss peramivir's availability during this global health emergency. The 'partners' are: Moksha8 Pharmaceuticals, Inc. for Brazil and Mexico. NT Pharma for China, and Neopharm for Israel. Another previously mentioned partner, Shionogi, is preparing to file for regulatory approval in Japan this year. BCRX has completed its peramivir PIII to support FDA's approval for influenza. In May it said that the EUA's review of IV piramivir has continued to make progress. Peramivir inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests it has shown activity against pandemic H1N1 viral strains. The previous UG in July was when BCRX announced positive results on 2 PIIIs of IV peramivil in patients with influenza. It seems that with some good news BCRX could get to test its Jan 2006 H at the $23 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2585)	1/6/2011 4:43:30 PM
From: Jibacoa	Respond to of 3722

LXRX had a good day today.<g> It closed up 45.83% on volume of >20M although there is slight profit taking AHs.<g> bigcharts.marketwatch.com It announced this morning data from a recently completed trial of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2. Those results demonstrated that the administration of a 300 mg tablet of LX4211 significantly increased total GLP-1 (p=0.001), active GLP-1 (p=0.032) and PYY (p=0.004),which are important mediators of glycemic and appetite control.<g> A single doses of LX4211 produced a rapid and significant improvement in post-prandial hyperglycemia. PYY has been studied as an anti-obesity agent, and GLP-1 is a mediator of insulin and glucagon secretion. As nutrients enter the small intestine, PYY and GLP-1 are co-secreted into the circulation by neuroendocrine cells of the gastrointestinal tract. LXRX CEO's stated: "We have established a solid tablet formulation suitable for further development and will continue to explore LX4211's unique mechanism of action in the treatment of diabetes and the hormonal control of metabolism." The stock traded above the ACTAY of $2.25 <g> With some good news the stock could get to the $5 level.<g> bigcharts.marketwatch.com Bernard